We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Repligen Corporation (RGEN - Free Report) reported first-quarter 2025 adjusted earnings per share of 39 cents, which beat the Zacks Consensus Estimate of 35 cents. The company had recorded adjusted earnings of 30 cents per share in the year-ago quarter.
Total revenues were $169 million, up 10% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 11% organically. Revenues beat the Zacks Consensus Estimate of $164 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Year to date, shares of Repligen have decreased 3.2% compared with the industry’s decline of 4.1%.
Image Source: Zacks Investment Research
More on RGEN's Q1 Earnings
Product revenues were $169.1 million, up 10.5% from the year-ago level. Royalty and other revenues amounted to $0.04 million, down almost 2.7% year over year.
Repligen’s business franchisees are categorized as filtration, chromatography, proteins and process analytics. Revenues from Repligen’s base business exclude COVID-related revenues and acquisition-related revenues. The company reported 14% organic non-COVID revenue growth for the first quarter.
Total orders grew nearly 20%, with all four franchises growing in double digits.
Revenues from biopharma and consumables grew more than 20% on a year-over-year basis during the first quarter, backed by strong orders. However, CDMO sales were slightly down on a year-over-year basis.
RGEN's Costs, Margins & Cash Position
Adjusted gross margin was 53.7%, higher than 49.2% in the year-ago period.
Adjusted research and development expenses totaled approximately $11.3 million, up 2.7% from the year-ago quarter’s level. Adjusted selling, general and administrative expenses rose around 10.4% to $56 million.
Adjusted operating income totaled $23.4 million compared with $13.6 million in the year-ago period.
Adjusted operating margin was 13.8% in the first quarter, higher than 8.9% in the year-ago quarter.
As of March 31, 2025, Repligen had cash and cash equivalents worth $697 million compared with $757 million as of Dec. 31, 2024.
RGEN's 2025 Guidance
Repligen now expects 2025 total revenues in the range of $695-$720 million, slightly higher than the previous expectation of $685-$710 million.
Adjusted EPS is now anticipated to be between $1.63 and $1.72, down from the prior expectation $1.67 to $1.76.
Adjusted operating income is now expected in the range of $95-$102 million compared with the previous projection of $99-$106 million.
Repligen anticipates adjusted gross margin between 52% and 53% for 2025, reflecting an increase of 100 basis points from the previous expectation.
The updated guidance reflects the impact of the recent acquisition of 908 Devices’ bioprocessing analytics business. Repligen purchased four devices from 908 Devices to strengthen its differentiated process analytical technology portfolio in March.
Repligen reiterated its organic revenue growth guidance in the range of 9.5%-13.5% for 2025.
Repligen Corporation Price, Consensus and EPS Surprise
In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 69 cents to 71 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 87 cents to 93 cents. Year to date, shares of ADMA have rallied 40.6%.
ADMA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.80%.
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.43 to $4.27 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.94 to $4.80. Year to date, shares of BEAM have lost 20.6%.
BEAM’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.92%.
In the past 60 days, estimates for Immunocore’s loss per share have narrowed from $1.61 to $1.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.81 to $1.68. Year to date, shares of IMCR have gained 3.3%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 31.91%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
Repligen Corporation (RGEN - Free Report) reported first-quarter 2025 adjusted earnings per share of 39 cents, which beat the Zacks Consensus Estimate of 35 cents. The company had recorded adjusted earnings of 30 cents per share in the year-ago quarter.
Total revenues were $169 million, up 10% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 11% organically. Revenues beat the Zacks Consensus Estimate of $164 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
Year to date, shares of Repligen have decreased 3.2% compared with the industry’s decline of 4.1%.
Image Source: Zacks Investment Research
More on RGEN's Q1 Earnings
Product revenues were $169.1 million, up 10.5% from the year-ago level. Royalty and other revenues amounted to $0.04 million, down almost 2.7% year over year.
Repligen’s business franchisees are categorized as filtration, chromatography, proteins and process analytics. Revenues from Repligen’s base business exclude COVID-related revenues and acquisition-related revenues. The company reported 14% organic non-COVID revenue growth for the first quarter.
Total orders grew nearly 20%, with all four franchises growing in double digits.
Revenues from biopharma and consumables grew more than 20% on a year-over-year basis during the first quarter, backed by strong orders. However, CDMO sales were slightly down on a year-over-year basis.
RGEN's Costs, Margins & Cash Position
Adjusted gross margin was 53.7%, higher than 49.2% in the year-ago period.
Adjusted research and development expenses totaled approximately $11.3 million, up 2.7% from the year-ago quarter’s level. Adjusted selling, general and administrative expenses rose around 10.4% to $56 million.
Adjusted operating income totaled $23.4 million compared with $13.6 million in the year-ago period.
Adjusted operating margin was 13.8% in the first quarter, higher than 8.9% in the year-ago quarter.
As of March 31, 2025, Repligen had cash and cash equivalents worth $697 million compared with $757 million as of Dec. 31, 2024.
RGEN's 2025 Guidance
Repligen now expects 2025 total revenues in the range of $695-$720 million, slightly higher than the previous expectation of $685-$710 million.
Adjusted EPS is now anticipated to be between $1.63 and $1.72, down from the prior expectation $1.67 to $1.76.
Adjusted operating income is now expected in the range of $95-$102 million compared with the previous projection of $99-$106 million.
Repligen anticipates adjusted gross margin between 52% and 53% for 2025, reflecting an increase of 100 basis points from the previous expectation.
The updated guidance reflects the impact of the recent acquisition of 908 Devices’ bioprocessing analytics business. Repligen purchased four devices from 908 Devices to strengthen its differentiated process analytical technology portfolio in March.
Repligen reiterated its organic revenue growth guidance in the range of 9.5%-13.5% for 2025.
Repligen Corporation Price, Consensus and EPS Surprise
Repligen Corporation price-consensus-eps-surprise-chart | Repligen Corporation Quote
RGEN's Zacks Rank & Stocks to Consider
Repligen currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ADMA Biologics Inc (ADMA - Free Report) , Beam Therapeutics Inc (BEAM - Free Report) and Immunocore Holdings PLC (IMCR - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 69 cents to 71 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 87 cents to 93 cents. Year to date, shares of ADMA have rallied 40.6%.
ADMA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.80%.
In the past 60 days, estimates for Beam Therapeutics' loss per share have narrowed from $4.43 to $4.27 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.94 to $4.80. Year to date, shares of BEAM have lost 20.6%.
BEAM’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.92%.
In the past 60 days, estimates for Immunocore’s loss per share have narrowed from $1.61 to $1.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.81 to $1.68. Year to date, shares of IMCR have gained 3.3%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 31.91%.